MGTA 456

Drug Profile

MGTA 456

Alternative Names: Cord blood stem cell therapy - Novartis; Expanded umbilical cord blood - Novartis; HSC-835; LFU835 expanded umbilical cord blood stem cells; MGTA-456; Spanlecortemlocel

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Magenta Therapeutics; Novartis
  • Class Stem cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Transplant rejection
  • Discontinued Haematological malignancies

Most Recent Events

  • 22 May 2017 Novartis withdraws prior to enrolment a phase I/II trial for Mucopolysaccharidosis-I, Metachromatic leukodystrophy, Globoid cell leukodystrophy and Cerebral adrenoleukodystropy (In infants, In children, In adolescents, In adults) in USA (Parenteral) (NCT02715505)
  • 13 May 2017 Pooled efficacy data from a clinical trials in Transplant rejection released by Magenta Therapeutics
  • 10 May 2017 Clinical trials in Transplant rejection in USA, before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top